About Genor Biopharma
Genor Biopharma is a publicly listed company based in Shanghai (China) founded in 2007. Developer of biosimilar monoclonal antibodies for treating multiple diseases. Genor Biopharma has raised $215.9 million across 2 funding rounds from investors including Temasek, Hillhouse and Haitong Capital. The company has 24 employees. Its chief executive, as recorded, is Feng Guo. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting.
Company details
Genor Biopharma is a developer of biosimilar monoclonal antibodies for treating multiple diseases. It has developed therapeutic monoclonal antibodies (mAbs), Fc-fusion proteins and recombinant therapeutic proteins. Its lead candidate, a trastuzumab biosimilar is in a multi-center clinical trial the second candidate, an infliximab biosimilar helps in treating cancer.
- Headquarters Shanghai, China
- Employees 24
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website genorbio.com
- Social LinkedIn
- Legal Name Genor Biopharma Holdings Limited
- Annual Revenue$346.86 M (USD)-2.27as on Dec 31, 2025
- Net Profit$55.63 M (USD)2.96as on Dec 31, 2025
- EBITDA$122.59 M (USD)3.26as on Dec 31, 2025
- Total Equity Funding$215.9M (USD)
in 2 rounds
- Latest Funding Round$160M (USD), Series B
Jun 2020
- InvestorsTemasek
& 4 more
- Employee Count24
Funding Insights of Genor Biopharma
Genor Biopharma has successfully raised a total of $215.9M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $160 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $215.9M
- Total Rounds 2
- Last Round Series B — $160M
- First Round $55.9M
(Jun 2018)
- Investors Count 5
All 2 funding rounds of Genor Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | $160M | Series B | – | Hillhouse | |
| Jun 2018 | $55.9M | Series A | – | Yingke Capital | – |
5 investors in total: 5 institutional.
Investors in Genor Biopharma
Genor Biopharma has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Temasek, Hillhouse and Haitong Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed with long-term focus. | hillhouseinvestment.com | New York, United States | ||
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
| crcapm.com | ||||
| htcc.sh.cn | ||||
Operates as an investment advisory firm providing expert guidance. | 2010 | yingkepe.com | Fuzhou, China |
Investor details for Genor Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genor Biopharma
11 people are tracked at Genor Biopharma (9 in leadership, 2 in team); the tracked headcount is 24.
| Name | Role | Group |
|---|---|---|
Feng Guo | CEO | Leadership |
Li Tong | Chief Medical Officer | Leadership |
Sally Chen | Pharmacovigilance Senior Director PV head | Leadership |
Shuhua Han | Chief Scientific Officer | Leadership |
Steven Kan (阚子义) | CTO/工艺生产质量负责人/CMC负责人 | Leadership |
Carol Yenlun Huang | Vice President, Head of Program and Portfolio Management | Leadership |
Wendy Yan | Vice President Of Business Development | Leadership |
Lily Zhu | HR VP | Leadership |
Qibin Liang | Chief Technology Officer | Leadership |
Rainy Gan | HR BP | Team |
chunlei liu | Cell cultute Engineer | Team |
Complete people profiles for Genor Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Genor Biopharma
Genor Biopharma is a publicly listed company on the HKEX with ticker symbol 6998 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Oct 2020
- Listed onHKG: 6998
- Listed entityGenor Biopharma Holdings Limited
- Exchange sectorHealth technology
- ISINKYG3871A1004
- Share price1.69 HKD (+0.9% on the day) · 2026-10-14
- Market capitalisation3,357,672,349.00 HKD
- Price to earnings5.0
- EPS (diluted, trailing year)0.33 HKD
- Volume (last session)553,000
Financials of Genor Biopharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.70B HKD | 433.0M HKD | 954.3M HKD |
| 2024 | 2.76B HKD | 420.6M HKD | 924.1M HKD |
| 2023 | -745.2M HKD | -686.8M HKD | |
| 2022 | 18.5M HKD | -849.1M HKD | -851.8M HKD |
| 2021 | -1.04B HKD | -1.03B HKD |
Detailed financial statements for Genor Biopharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Genor Biopharma
4 dated milestones of Genor Biopharma across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Genor Biopharma is founded.
- Funding First funding round of $55.9M.
- Funding Latest funding round, Series B, of $160.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Genor Biopharma
Websites that share an audience with Genor Biopharma (genorbio.com).
Websites whose visitors overlap most with Genor Biopharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
uwmrf.org | uwmrf.org | 100% | #4,562,419 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genor Biopharma
Complete news archive for Genor Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genor Biopharma
Genor Biopharma was founded in 2007 and raised its 1st funding round 11 years after it was founded.
Genor Biopharma is headquartered in Shanghai, China.
Feng Guo is the CEO of Genor Biopharma, as recorded in our data.
Genor Biopharma is a funded company, having raised a total of $215.9M across 2 funding rounds to date. The company's 1st funding round was a Series A of $55.9M, raised on Jun 2018.
Genor Biopharma has 24 employees.
Annual revenue of Genor Biopharma is $346.86M as on Dec 31, 2025.
Genor Biopharma is a developer of biosimilar monoclonal antibodies for treating multiple diseases. It has developed therapeutic monoclonal antibodies (mAbs), Fc-fusion proteins and recombinant therapeutic proteins. Its lead candidate, a trastuzumab biosimilar is in a multi-center clinical trial the second candidate, an infliximab biosimilar helps in treating cancer.
Yes, Genor Biopharma is publicly traded on HKEX under the ticker symbol 6998.
Genor Biopharma has 5 investors. Key investors include Temasek, Hillhouse, Haitong Capital, CR Capital Management, and Yingke Capital.